NASDAQHealth CareMedical - DistributionSnapshot 2026-08-31
Reading HSIC? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Primary pillar under pressure — Maintain mid-single digit EBITDA growth in 2026: EBITDA margin 7.0% vs 7.5% prior year.
Henry Schein grows sales about 3% to 5% yearly. Profit rises with mid-single digit EBITDA growth. EPS is on track for $5.3 in 2026. The company beats earnings and revenue estimates consistently.
Growth could slow if medical demand weakens. Management changes add uncertainty. Profit margins may compress if cost savings fall short.
The market prices in about 4% revenue growth and values the stock slightly below our fair value near $90. Our fair value is 6% above the Street median, reflecting confidence in steady growth and profit.
Breaks if: EBITDA growth falls below 4% in FY26
Breaks if: EPS guidance falls below $5.23 for FY26
Breaks if: YoY revenue growth falls below 3% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on consistent growth. The current thesis state is intact, supported by strong recent financial performance and management's commitment to growth targets.
Valuation is neutral compared to peers, indicating that the market has priced in some fragility due to weak execution quality. The expectations gap suggests that the market anticipates slightly lower performance than what HSIC has recently delivered.
Management is on track to achieve its sales and earnings growth targets for 2026, with strong recent results backing these goals. However, there is a moderate risk due to the company's recent history of earnings misses.
The long-term thesis hinges on maintaining growth momentum and avoiding negative guidance changes. Additionally, the performance of sector bellwethers and broader economic indicators, like job reports, will be crucial in shaping HSIC's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat and reaffirmed EPS guidance support the thesis. However, the exit of three executives may disrupt strategic initiatives.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, HSIC's fundamentals appear solid, but caution is warranted due to potential external risks. Not investment advice.
